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CASE REPORT
We experienced a case of primary pulmonary biphasic synovial sarcoma, which was confirmed by
immunohistochemistry and molecular testing of SYT-SSX2 fusion transcripts. The patient was a 61-year-old man
who presented with a well-defined mass in the left upper lung field on chest radiography. Left upper lobectomy
with lymph node dissection was performed. Histological and immunophenotypic features were consistent with
biphasic synovial sarcoma. Reverse transcriptase polymerase chain reaction, performed using RNA extracted
from frozen tumor samples for the detection of SYT-SSX fusion gene, amplified a single 331-bp fragment that was
characteristic of the SYT-SSX2 fusion transcripts. We report a case of primary pulmonary biphasic synovial
sarcoma, which was confirmed by SYT-SSX2 fusion transcripts, and present a brief review of the literature on
Korean cases.  (Korean J Intern Med 2010;25:331-336)
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INTRODUCTION
Pulmonary sarcoma usually occurs through metastasis
from other locations such as the extremities, and primary
pulmonary sarcoma accounts for < 0.5% of all pulmonary
malignancies [1]. Cytogenetic studies have detected the
chromosomal translocation t (x;18) (p11;q11) in synovial
sarcoma and have determined that the translocation fuses
the SYT gene from chromosome 18 with the SSX1 and
SSX2 genes on chromosome X to form SYT-SSX1 or
SYT-SSX2, which is thought to function as an aberrant
transcriptional regulator [1-3]. The fusion genes detected
by reverse transcriptase polymerase chain reaction (RT-
PCR) have been used to make a definitive diagnosis of
synovial sarcoma [3], and it has been reported that they
are related to the histological characteristics and prognosis
of this tumor. It has also been demonstrated that patients
with the SYT-SSX2 fusion transcripts have a better
prognosis than those with SYT-SSXI fusion transcripts
[2]. 
Only a few reports have examined primary pulmonary
synovial sarcoma in Korea. Here, we report a case of primary
pulmonary biphasic synovial sarcoma that was confirmed
by detection of an SYT-SSX2 fusion gene, and present a
brief review of the literature concerning this form of tumor
in Korean patients.
CASE REPORT
A 61-year-old man presented with an incidentally found
mass in the lung, which was detected by a health-screening
program. He had a smoking history of 30 pack-years. On
admission, his vital signs were as follows: blood pressure,332 The Korean Journal of Internal Medicine Vol. 25, No. 3, September 2010
120/80 mmHg; pulse rate, 75/min; respiration rate, 20/
min; and body temperature, 36.5˚C . He was not chronically
ill, and he had clear consciousness. Chest auscultation
revealed no abnormal heart and lung sounds. No enlarged
lymph nodes were found in the head, neck, or extremities.
Simple chest X-ray revealed a well-defined round mass in
the left upper lung field (Fig. 1A). Computed tomography
(CT) of the chest showed a 3 ×3-cm, well-defined, lobulated
round mass in the anterior segment of the left upper lobe,
and on contrast images, the mass showed heterogeneous
enhancement with ≥ 20 HU difference in enhancement
(Fig. 1B). Positron emission tomography (PET)-CT showed
a pulmonary mass at the same site with an increased F18-
fluorodeoxyglucose (FDG) standardized uptake value
(SUV) of 8.1. No increase in the FDG uptake rate in the
lymph nodes was detected at the mediastinum and both
pulmonary hila (Fig. 2). Radioisotope bone scans revealed
no abnormal findings. Peripheral blood tests showed
white blood cells, 7,770/mm3; hemoglobin, 13.4 g/dL; and
platelets 258,000/mm3. No abnormal findings were
observed in routine chemistry tests, serum electrolytes,
Figure 1. (A) Chest radiograph shows a left upper lobe mass. (B) On chest CT scan, a 3 × 3-cm lobulated, heterogeneous enhancing mass
was noted in the anterior segment of the left upper lobe.
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Figure 2. F18-fluorodeoxyglucose positron emission tomography
(PET) fused coronal image; fusion PET demonstrates a moderately
hypermetabolic mass in the left upper lobe.
Figure 3. Light microscopy shows spindle cells with focal
epithelial differentiation (H&E, ×400). blood coagulation tests, and urinalysis.
Light microscopic examination of the specimens obtained
through percutaneous lung biopsy revealed a spindle-cell-
type neoplastic hyperplasia and localized areas of epithelial
cells around the spindle cells. Immunohistochemistry
displayed positive reactivity for Bcl-2, CD99, and β-catenin,
with a strong possibility of a solitary fibrous tumor.
However, a definite diagnosis could not be made because
the tumor was negative for CD34, for which most solitary
fibrous tumors are positive. 
Left upper lobe resection with lymph node dissection
was performed, and a 3.8 × 2.8 × 25-cm, well-defined,
whitish-yellow, smooth-surfaced oval mass was found.
Light microscopic examination of the surgical specimen
showed spindle cells and focal epithelial cells with mitotic
activity of 10/10 HPFs (Fig. 3). By immunohistochemistry,
the epithelial cells were positive for epithelial membrane
antigen (EMA), whereas the spindle cells were negative. In
addition, the tumor was positive for S-100, CD99, and Bcl-
2, but negative for CD34, desmin, cytokeratin pan (CK-
pan), thyroid transcription factor 1 (TTF-1), surfactant
protein A (SP-A), leading to a diagnosis of primary
pulmonary biphasic synovial sarcoma (Fig. 4).
RT-PCR was performed according to the method of
Kawai et al. [2]. Total RNA was isolated from the frozen
sections obtained from the tumor tissue using the
acid/guanidinum/phenol/chloroform method, and 1 µg
RNA was transcribed using Superscript II Reverse
Transcriptase (GIBCO, Gaithersburg, MD, USA) and
random hexamers. The cDNA was amplified using the
forward primer (5’CAACAGCAAGATGCATACCA3’) and
reverse primer (5’CACTTGCTATGCACCTGATG3’ for
SSX; 5’GGTGCAGTTGTTTCCCATCG3’ for SSX1; or
5’GGCACAGCTCTTTCCCATCA3’ for SSX2). RT-PCR was
Park JS, et al. Primary pulmonary biphasic synovial sarcoma    333
Figure 4. The results of immunohistochemical staining for CD34 (A), Bcl-2 (B), CD99 (C), and epithelial membrane antigen (EMA)
(D, ×400). The tumor cells were completely negative for CD34 and focally positive for Bcl-2. The malignant epithelial cells were
positive for EMA, but the spindle cells were negative for EMA.  
A B
C Dcarried out under the following conditions: 35 amplification
cycles, each consisting of denaturation at 95˚C for 1
minute, annealing at 58˚C or 60˚C for 1 minute, and
extension at 72˚Cfor 1 minute, followed by 10 minutes of
an additional extension step at 72˚C. The PCR products
were then electrophoresed on a 1.5% agarose gel, stained
with ethidium bromide, and subsequently identified as an
SYT-SSX (585 bp) or SYT-SSX2 (331 bp) gene (Fig. 5).
Chest radiographs taken at 16 months after surgery
showed pleural effusion on the left side. Chest CT revealed
a left pleura-based mass, enlarged mediastinal lymph
nodes, and suspected malignant hydrothorax. PET-CT
scans showed a left pleural mass with an increased F18-
FDG SUV of 6.5. A percutaneous lung biopsy was performed
to make a definitive diagnosis of the left pleura-based
mass. Light microscopy and immunohistochemistry
confirmed the recurrence of synovial sarcoma. The patient
was scheduled for total resection of the tumor along with
adjacent chemoradiotherapy.  
DISCUSSION
Synovial sarcoma can be histopathologically divided
into biphasic, monosphasic fibrous, monophasic epithelial,
and poorly differentiated types. In cases of the biphasic
type, both epithelial and spindle cells are present; therefore,
the diagnosis is relatively easy to make. However, in cases
of the monophasic type, which has homogeneous patterns
of spindle cells, immunohistochemical staining is needed
to distinguish this tumor from other spindle-cell-type
tumors such as fibrosarcoma, hemangiopericytoma,
leiomyosarcoma, and spindle cell carcinoma [1]. Coindre
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Figure 5. Analysis of SYT-SSX fusion transcripts in synovial
sarcoma. Reverse transcriptase polymerase chain reaction (RT-
PCR) of total RNA from a patient with synovial sarcoma was
performed using the SYT-SSX (consensus), SSX1, and SSX2
primers. The PCR products were then isolated by electrophoresis
on an agarose gel. The size of the SYT-SSX product was 585 bp, and
that of the SYT-SSX2product was 331 bp.
500
500
58˚C 60˚C
SYT-SSX : 585bp
SYT-SSX2 : 331bp
12312 3
1 : Blood normal
2 : Tissue tumor
3 : Negative
Table 1. Clinical features of primary pulmonary synovial sarcoma in Korea
Reference Sex/Age Symptoms Location Maximum Histological Immunohistochemical findings Treatment Prognosis
size, cm subtype Positive Negative
9 F/60 Cough RLL 5 Monophasic vim, Bcl-2 ck, EMA, SMA, S-100, RL lobectomy NA
CD34, C-kit, CD68
10 M/31 Left  RUL 6 Poorly  EMA, ck NA RU lobectomy,  6 mon NED
hemiplegia differentiated Partial pleurectomy, 
Brain tumor resection,
Chemotherapy
11 F/59 Chest pain Left  4 Biphasic ck, EMA, vim S-100, CD34 Thoracostomy 5 mon DOD
pleuropulmonary
12 F/36 Dyspnea LUL 3.5 Biphasic EMA, ck vim, S-100, des, LU lobectomy 15 mon NED
α-SMA,FVIIRA, CEA
13 M/45 Incidental finding LUL 7 Biphasic ck, EMA, vim NA LU lobectomy NA
14 M/28 Dyspnea LLL 10 Biphasic vim, ck, EMA NA Left pneumonectomy NA
Present 
F/61 Incidental finding LUL 3.8 Biphasic
EMA, S-100, des, CKpan, CD34,
LU lobectomy 16 mon AWD case Bcl-2, CD99 TTF-1, SP-A
RLL, right lower lobe; vim, vimentin; ck, cytokeratin; EMA, epithelial membrane antigen; SMA, smooth muscle antigen; NA, not
available; RUL, right upper lobe; NED, no evidence of disease; DOD, died of disease; LUL, left upper lobe; des, desmin; FVIIRA, factor
VII related antigen; CEA, carcinoembryonic antigen; LLL, left lower lobe; TTF-1, thyroid transcription factor-1; AWD, alive with disease.et al. [3] have suggested that the most reliable findings are
positivity for EMA or cytokeratins AE1/AE3 and negativity
for CD34. However, Begueret et al. [ ] have reported that
this tumor can be positive for the S-100 protein, α-smooth
muscle actin, c-kit, CD34, and calretinin. Based on these
results, it is conceivable that immunohistochemistry is not
the most accurate test for synovial sarcoma. In our case,
the tumor mass was negative for CD34, which
distinguished this tumor from fibrosar-coma. EMA-
negative spindle cells were observed, in contrast to EMA-
positive epithelial cells. Based on these findings, our case
was diagnosed as a biphasic synovial sarcoma. 
Recently, through cytogenetic studies, the translocation
of specific genes has been identified in various synovial-
sarcoma-like forms of sarcoma. The chromosomal translo-
cation t (x;18) (p11;q11) has been found in 95% of synovial
sarcomas in which the SYT gene located on the long arm
of chromosome 18 is fused with the SSX1 or SSX2 gene
located on the short arm of chromosome X, forming a new
SYT-SSX1 or SYT-SSX2 fusion gene. The SYT-SSX fusion
gene induces the development of sarcoma. Although the
biological role of the fusion gene has yet to be identified, it
has been reported that the SYT protein functions as a
transcriptional regulator, and the SSX protein functions as
a complement for the transcriptional inhibitor [1]. The
SYT-SSX1 fusion gene has been found in the majority of
biphasic synovial sarcomas, whereas the SYT-SSX2 fusion
gene has been detected in the majority of monophasic
synovial sarcomas [2]. Nevertheless, Ladanyi et al. [5]
have reported that histological classification does not
always coincide with the fusion-gene classification. In our
case of biphasic synovial sarcoma, an SYT-SSX2 gene was
detected. The detection of fusion genes has been reported
to have a sensitivity of 96% and a specificity of 100% for the
diagnosis of synovial sarcoma [6], which has made this
technique a widely used and important method for
establishing a definite diagnosis of this tumor.
A total of six cases of primary pulmonary synovial
sarcoma have been reported in Korea (Table 1) [7-12]. Our
case is the first that confirmed the presence of an SYT-SSX
fusion gene. Previous cases in Korea have occurred in
patients aged 28 to 61 years (mean, 45.7 years), and four
occurred in women. No specific symptoms were found in
two cases. The tumor size was 3.5 to 10 cm (mean, 5.6
cm). The tumor developed in the left lung in five cases. As
for the histological classification, five were biphasic type,
one was monophasic type, and another was poorly
differentiated type. The epithelial cells were positive for
EMA or cytokeratin and negative for CD34. At the initial
diagnosis, pneumonectomy was performed in all cases,
except a case with accompanying pleural invasion and
malignant pleural effusion. According to the report by
Begueret et al. [4], many cases of synovial sarcoma are
mistakenly diagnosed as spindle-cell tumors such as
fibrosarcoma or hemangiopericytoma because of the
absence of methods that give a definite diagnosis of
synovial sarcoma. Recently, cases of synovial sarcoma
have increased due to the aforementioned diagnostic tool.
The detection of the fusion gene will assist in making a
definite diagnosis of synovial sarcoma.
Several reports have examined the relationship between
the SYT-SSX fusion gene and the prognosis of synovial
sarcoma. Although some investigators have indicated that
patients with SYT-SSX1 fusion genes have a poorer
prognosis than do those with SYT-SSX2 fusion genes,
Guillou et al. [6] have reported contradictory results.
Further studies with a larger number of cases are needed
to verify the relationship between the patterns of fusion
genes and the prognosis of synovial sarcoma. 
We have reported a case that was definitively diagnosed
as primary pulmonary biphasic sarcoma based on the
detection of an SYT-SSX2fusion gene.
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